At the ADA Scientific Sessions, an endocrinologist chronicles how incremental improvements have curtailed pricing competition.
OPINION – A Libre user says it’s a poor substitute for a CGM.
Advocates argue for both treatments at the ADA 77th Scientific Sessions.
At times dubbed an artificial pancreas, the 670G represents a leap forward in automated insulin delivery.
The two children are credited with doing everything right to get their mother the help she needed.
Changes in air pressure might cause an issue, the pump maker warns.
State lawmakers want to know why insulin prices keep increasing.
Novo Nordisk submitted the rapid-acting insulin to the agency in late March.
The agency stopped short of outlawing the sale of them, however.
Holly Murphy’s recovery will be long and expensive. You can donate to help.
Dr. Jennifer Sherr describes her experience as an artificial pancreas researcher and trial participant.
A mother shares how a records mishap has led to a trip to the hospital for her daughter with Type 1 diabetes.
A certified diabetes educator discusses why diabetes ups the risk of periodontal disease.
A woman with Type 1 chronicles a difficult journey to use the medicine that keeps her both alive and unwell.
Abbott, the maker of the Libre, touts an analysis of user data of the glucose monitoring system.
The organization launches workshops both in the U.S. and abroad.
The pump, which is sold internationally, could fail to charge because of it.
A researcher on diabetes and exercise describes why exercise elevates risk of DKA for people with Type 1 diabetes.
A woman with Type 1 claims a doctor withheld a prescription even though she was running out of insulin.
A team of international researchers release new guidelines based on the accumulation of research on the subject.